HK1254083A1 - 用於治療癌症的缺氧活化前驅藥物和抗血管生成劑 - Google Patents

用於治療癌症的缺氧活化前驅藥物和抗血管生成劑

Info

Publication number
HK1254083A1
HK1254083A1 HK18113147.5A HK18113147A HK1254083A1 HK 1254083 A1 HK1254083 A1 HK 1254083A1 HK 18113147 A HK18113147 A HK 18113147A HK 1254083 A1 HK1254083 A1 HK 1254083A1
Authority
HK
Hong Kong
Prior art keywords
cancer
administration
treatment
antiangiogenic agents
hypoxia activated
Prior art date
Application number
HK18113147.5A
Other languages
English (en)
Inventor
Stewart Kroll
John Curd
Charles Hart
Jessica Sun
Original Assignee
Threshold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Threshold Pharmaceuticals Inc filed Critical Threshold Pharmaceuticals Inc
Publication of HK1254083A1 publication Critical patent/HK1254083A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK18113147.5A 2010-07-12 2018-10-15 用於治療癌症的缺氧活化前驅藥物和抗血管生成劑 HK1254083A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36361010P 2010-07-12 2010-07-12
US201161470412P 2011-03-31 2011-03-31
US201161470812P 2011-04-01 2011-04-01

Publications (1)

Publication Number Publication Date
HK1254083A1 true HK1254083A1 (zh) 2019-07-12

Family

ID=45470020

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18113147.5A HK1254083A1 (zh) 2010-07-12 2018-10-15 用於治療癌症的缺氧活化前驅藥物和抗血管生成劑

Country Status (11)

Country Link
US (2) US20140010805A1 (zh)
EP (2) EP2593139B1 (zh)
JP (1) JP6066421B2 (zh)
KR (1) KR20130045341A (zh)
CA (1) CA2803675A1 (zh)
ES (2) ES2877629T3 (zh)
HK (1) HK1254083A1 (zh)
MX (1) MX2012014428A (zh)
RU (1) RU2597844C2 (zh)
WO (1) WO2012009288A2 (zh)
ZA (1) ZA201300692B (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003625B2 (en) 2005-06-29 2011-08-23 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs
BRPI0710645A2 (pt) 2006-04-07 2012-03-20 The Procter & Gamble Company Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
KR20140038390A (ko) 2011-04-01 2014-03-28 쓰레솔드 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
CN103458880A (zh) * 2011-04-15 2013-12-18 施瑞修德制药公司 口服给药的单位剂型
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
WO2013096687A1 (en) 2011-12-22 2013-06-27 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer
US20150005262A1 (en) * 2011-12-22 2015-01-01 Threshold Pharmaceuticals, Inc. Hypoxia activated prodrugs and mtor inhibitors for treating cancer
EP2810076A4 (en) * 2012-01-31 2015-07-01 Threshold Pharmaceuticals Inc PRÄDIKTIVER BIOMARKER FOR HYPOXIA-ACTIVATED PRODRUGTHERAPY
JP6360438B2 (ja) * 2012-02-21 2018-07-18 モレキュラー テンプレーツ，インコーポレイテッド 癌の治療
AU2013204313C1 (en) * 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
AU2015264805B2 (en) * 2012-06-01 2017-04-13 Bionomics Limited Combination Therapy
WO2014062856A1 (en) * 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
WO2014069063A1 (ja) 2012-10-29 2014-05-08 京セラ株式会社 弾性表面波センサ
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
WO2014169035A1 (en) * 2013-04-10 2014-10-16 Threshold Pharmaceuticals, Inc. Predictive and response biomarker for th-302 anti-cancer therapy
EP3024490A1 (en) 2013-07-26 2016-06-01 Threshold Pharmaceuticals, Inc. Treatment of pancreatic cancer with a combination of a hypoxia-acti vated prodrug and a taxane
WO2015069489A1 (en) 2013-11-06 2015-05-14 Merck Patent Gmbh Predictive biomarker for hypoxia-activated prodrug therapy
WO2015138882A1 (en) 2014-03-14 2015-09-17 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US10159659B2 (en) 2014-07-02 2018-12-25 Bionomics Limited Predicting response to cancer therapy
US10131683B2 (en) 2014-07-17 2018-11-20 Molecular Templates, Inc. TH-302 solid forms and methods related thereto
WO2016014390A1 (en) * 2014-07-25 2016-01-28 Merck Patent Gmbh Compositions and methods for mek inhibitor combination therapy in the treatment of cancer
TWI674258B (zh) 2015-03-10 2019-10-11 大陸商深圳艾欣達偉醫藥科技有限公司 Ｄｎａ烷化劑
SG10201913709QA (en) 2015-04-02 2020-03-30 Ascentawits Pharmaceuticals Ltd Nitrobenzyl derivatives of anti-cancer agents
JP7327900B2 (ja) 2015-06-24 2023-08-16 スレッシュホールド ファーマシューティカルズ， インコーポレイテッド アジリジン含有ｄｎａアルキル化剤
BR112018005499A2 (pt) 2015-09-23 2018-10-09 Aerpio Therapeutics Inc métodos de tratamento de pressão intraocular com ativadores de tie-2.
KR20240051965A (ko) 2021-08-27 2024-04-22 아센타위츠 파마슈티컬즈 리미티드 Th-302를 이용한 parp 억제제에 내성이 있는 환자의 치료
WO2023025291A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 冻干制剂溶液及冻干制剂、方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9909612D0 (en) 1999-04-26 1999-06-23 Cancer Res Campaign Tech N-protected amines and their use as prodrugs
NZ521851A (en) 2002-10-08 2005-02-25 Auckland Uniservices Ltd Nitroaniline-based unsymmetrical mustard alkylating agents for gene dependent enzyme prodrug therapy
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
JP4760712B2 (ja) 2003-10-31 2011-08-31 オークランド ユニサーヴィスィズ リミテッド 新規ニトロフェニルマスタードおよびニトロフェニルアジリジンアルコールおよびそれらの対応するリン酸エステルおよびターゲットが決められた細胞毒性剤としてのそれらの使用
JP4947717B2 (ja) * 2004-07-20 2012-06-06 ジェネンテック， インコーポレイテッド アンジオポエチン様４タンパク質のインヒビター、組み合わせ、およびそれらの使用
US8003625B2 (en) * 2005-06-29 2011-08-23 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs
CA2624707A1 (en) 2005-10-03 2007-04-12 Genetix Pharmaceuticals, Inc. Method for selectively depleting hypoxic cells
WO2008033041A1 (en) * 2006-09-11 2008-03-20 Auckland Uniservices Limited Cancer treatment
EP2114157B1 (en) 2006-12-26 2021-05-26 ImmunoGenesis, Inc. Phosphoramidate alkylator prodrug for the treatment of cancer
JP5731372B2 (ja) * 2008-04-10 2015-06-10 ヴァージニア コモンウェルス ユニバーシティ 癌治療用腫瘍低酸素の誘発
JP2011523551A (ja) * 2008-05-15 2011-08-18 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 血管形成の調節の新規ターゲット
EP2350664B1 (en) 2008-10-21 2021-05-19 ImmunoGenesis, Inc. Treatment of cancer using the hypoxia activated prodrug th-302 in combination with docetaxel or pemetrexed

Also Published As

Publication number Publication date
EP2593139A4 (en) 2013-11-27
JP2013531038A (ja) 2013-08-01
KR20130045341A (ko) 2013-05-03
MX2012014428A (es) 2013-03-05
JP6066421B2 (ja) 2017-01-25
CA2803675A1 (en) 2012-01-19
EP3311835B1 (en) 2021-03-24
EP2593139A2 (en) 2013-05-22
WO2012009288A2 (en) 2012-01-19
ZA201300692B (en) 2013-09-25
US20140010805A1 (en) 2014-01-09
ES2649340T3 (es) 2018-01-11
RU2013103027A (ru) 2014-08-20
US20190060275A1 (en) 2019-02-28
RU2597844C2 (ru) 2016-09-20
EP3311835A1 (en) 2018-04-25
EP2593139B1 (en) 2017-08-23
ES2877629T3 (es) 2021-11-17
WO2012009288A9 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
HK1254083A1 (zh) 用於治療癌症的缺氧活化前驅藥物和抗血管生成劑
EP2740793A4 (en) MEDICINAL PREPARATION FOR CANCER TREATMENT AND / OR PREVENTION
EP2740795A4 (en) MEDICAMENT COMPOSITION FOR TREATMENT AND / OR PREVENTION OF CANCER
EP2740798A4 (en) DRUG COMPOSITION FOR CANCER TREATMENT AND / OR PREBUILDING
IL225471B (en) Preparations for the prevention and treatment of cancer
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
PL2532680T3 (pl) Kompozycja medyczna do leczenia raka i/lub zapobiegania
PT2532367T (pt) Agente farmacêutico para o tratamento e/ou prevenção do cancro
EP2688594A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
IL251083A0 (en) Compounds and preparations for the treatment of cancer
EP2558085A4 (en) COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER
ZA201300762B (en) Novel combination therapy for the treatment of cancer
HK1201730A1 (zh) 抗癌劑的副作用的預防劑和/或治療劑
IL275636A (en) Medical combination for cancer treatment
EP2661434A4 (en) NEW URGES FOR THE TREATMENT AND PREVENTION OF CANCER
EP2547368A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT
EP2836217A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE ADMINISTRATION OF ANTICANCER CHEMOTHERAPEUTIC AGENTS
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
IL223219A0 (en) Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies
IL221238A0 (en) Pharmaceutical compositions and methods for the treatment and prevention of cancer
GB201100404D0 (en) Combination of metformin and syrosingopine for the treatment of cancer and immunosuppression